Are UK consultants interested in pragmatic trials for those with schizophrenia?

Adams, Clive E; Gray, Roland W; Daniels, Judith K.; Thornley, Ben; Philpott, Hamish; Wahlbeck, Kristian

doi:10.1016/s0920-9964(00)90887-9

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2000

2007

Publication Types

Select...

Article2

Other1

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the dose that is chosen in efficacy studies may well be higher than most clinicians might use in routine care. In addition, haloperidol is not the most commonly used antipsychotic in many health care systems (29), nor is it the treatment that a new drug would necessarily replace if it were introduced into routine practice.…”

Section: Discussionmentioning

confidence: 99%

Randomized controlled trials in schizophrenia: a critical perspective on the literature

Gilbody

Wahlbeck

Adams

2002

Acta Psychiatr Scand

Self Cite

View full text Add to dashboard Cite

Explanatory designs are a necessary but insufficient step in establishing the true worth of interventions in schizophrenia. Research from other spheres of mental health and wider health care suggest that pragmatic trials are feasible. This design allows large scale trials to be conducted which include patients which we would recognize from routine practice and which record outcomes which are of genuine interest to decision-makers.

show abstract

Section: Discussionmentioning

confidence: 99%